Clinical Trials Logo

Filter by:
NCT ID: NCT04318080 Active, not recruiting - Clinical trials for Classical Hodgkin Lymphoma

Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

TIRHOL
Start date: August 20, 2020
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to evaluate the efficacy of tislelizumab in participants with relapsed/refractory classical Hodgkin lymphoma, as measured by the overall response rate per the Lugano Classification, and as determined by the investigator.

NCT ID: NCT04316013 Recruiting - Clinical trials for Non Small Cell Lung Cancer

Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial

Start date: July 31, 2020
Phase: Phase 3
Study type: Interventional

VAPOR-C is a randomised study of the impact of IV versus inhaled anaesthesia (propofol versus sevoflurane) and lidocaine versus no lidocaine on duration of disease free survival inpatients with either colorectal or non small cell lung cancer.

NCT ID: NCT04314986 Completed - Healthy Volunteers Clinical Trials

Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers

Start date: June 28, 2019
Phase: Phase 1
Study type: Interventional

A study to assess multiple ascending doses of AR882 in healthy adult males.

NCT ID: NCT04314934 Active, not recruiting - Alzheimer Disease Clinical Trials

OLE of Phase 2b/3 Study ANAVEX2-73-AD-004

ATTENTION-AD
Start date: October 10, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

This is a Phase 2b/3 open-label extension study to evaluate the effects of ANAVEX2-73 on safety and effficacy of daily treatment.

NCT ID: NCT04314544 Recruiting - Clinical trials for Active Psoriatic Arthritis

Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)

Start date: July 1, 2020
Phase: Phase 3
Study type: Interventional

This is a multicenter Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of tildrakizumab in Subjects with Active Psoriatic Arthritis I (INSPIRE 1)

NCT ID: NCT04314531 Active, not recruiting - Clinical trials for Active Psoriatic Arthritis

Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)

Start date: July 1, 2020
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blinded, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tildrakizumab compared to placebo in anti-TNF naïve subjects with active PsA .

NCT ID: NCT04314362 Completed - Clinical trials for Meibomian Gland Dysfunction

Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)

Start date: July 14, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

Single-center, single-masked (the individual(s) performing efficacy and safety measures will be masked to treatment assignment for the patient(s) they are assessing), vehicle-controlled, randomized study.

NCT ID: NCT04313881 Terminated - Clinical trials for Myelodysplastic Syndromes

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)

ENHANCE
Start date: September 9, 2020
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of magrolimab in combination with azacitidine compared to that of azacitidine plus placebo in previously untreated participants with intermediate/high/very high risk myelodysplastic syndrome (MDS) by Revised International Prognostic Scoring System (IPSS-R) as measured by complete remission (CR) and overall survival (OS).

NCT ID: NCT04313608 Completed - B-cell Lymphoma Clinical Trials

A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

Start date: June 4, 2020
Phase: Phase 1
Study type: Interventional

This study is designed to evaluate the safety and efficacy of glofitamab or mosunetuzumab in combination with gemcitabine and oxaliplatin (Glofit-GemOx or Mosun-GemOx) in participants with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL).

NCT ID: NCT04313166 Completed - Clinical trials for Amyotrophic Lateral Sclerosis

Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001

Start date: March 19, 2020
Phase: Phase 2
Study type: Interventional

Provides up to six months treatment with CuATSM for subjects who have successfully completed study CMD-2019-001